Abstract
The development of biomarkers for Alzheimer disease (AD) has led to the origin of suspected non-AD pathophysiology (SNAP) — a heterogeneous biomarker-based concept that describes individuals with normal amyloid and abnormal tau and/or neurodegeneration biomarker status. In this Review, we describe the origins of the SNAP construct, along with its prevalence, diagnostic and prognostic implications, and underlying neuropathology. As we discuss, SNAP can be operationalized using different biomarker modalities, which could affect prevalence estimates and reported characteristics of SNAP in ways that are not yet fully understood. Moreover, the underlying aetiologies that lead to a SNAP biomarker profile, and whether SNAP is the same in people with and without cognitive impairment, remains unclear. Improved insight into the clinical characteristics and pathophysiology of SNAP is of major importance for research and clinical practice, as well as for trial design to optimize care and treatment of individuals with SNAP.
Key points
-
Suspected non-Alzheimer disease (AD) pathophysiology (SNAP) is a heterogeneous biomarker-based concept describing individuals with a normal amyloid biomarker and abnormal tau and/or neurodegeneration biomarkers.
-
SNAP is common in people with normal cognition (NC) or mild cognitive impairment (MCI) and is associated with a reduced frequency of the apolipoprotein E ε4 allele (a key genetic risk factor for AD) compared with individuals with abnormal amyloid biomarkers.
-
Evidence shows that NC-SNAP is associated with a low risk of cognitive decline over 7 years, whereas MCI-SNAP is associated with an increased risk of developing clinical AD dementia.
-
Cerebrospinal fluid (CSF) proteomics studies suggest a disturbance in amyloid metabolism and involvement of the blood–CSF barrier in people with MCI-SNAP.
-
Neuropathological studies indicate that SNAP can represent early AD pathology, presumed AD-spectrum pathologies such as primary age-related tauopathy or non-AD pathologies that occur with increased frequency in AD, such as limbic-predominant age-related TAR DNA-binding protein 43 encephalopathy neuropathological change, argyrophilic grain disease or Lewy body disease.
-
More sensitive biomarkers of amyloid pathology and novel biomarkers for non-AD pathologies are needed to identify the underlying cause of SNAP in vivo and provide appropriate treatments.
Similar content being viewed by others
References
Glenner, G. G. & Wong, C. W. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131–1135 (1984).
Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002).
Jack, C. R. Jr et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 257–262 (2011).
Jack, C. R. Jr et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann. Neurol. 71, 765–775 (2012).
Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Assocation workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 280–292 (2011).
Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 9, 119–128 (2010).
Power, M. C. et al. Combined neuropathological pathways account for age-related risk of dementia. Ann. Neurol. 84, 10–22 (2018).
Kawas, C. H. et al. Multiple pathologies are common and related to dementia in the oldest-old: the 90+ study. Neurology 85, 535–542 (2015).
Knopman, D. S. et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576–1582 (2012).
Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx 1, 213–225 (2004).
Hansson, O. et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 14, 1470–1481 (2018).
Klunk, W. E. et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306–319 (2004).
Schwarz, C. G. et al. Considerations for performing level-2 Centiloid transformations for amyloid PET SUVR values. Sci. Rep. 8, 7421 (2018).
Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457–468 (2013).
Jack, C. R. Jr et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).
Jack, C. R. et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 16, 435–444 (2017).
Jack, C. R. Jr et al. Suspected non-Alzheimer disease pathophysiology – concept and controversy. Nat. Rev. Neurol. 12, 117–124 (2016).
Dodich, A. et al. The A/T/N model applied through imaging biomarkers in a memory clinic. Eur. J. Nucl. Med. Mol. Imaging 47, 247–255 (2020).
Ebenau, J. L. et al. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology 95, e46–e58 (2020).
Ingala, S. et al. Application of the ATN classification scheme in a population without dementia: findings from the EPAD cohort. Alzheimers Dement. 17, 1189–1204 (2021).
Ekman, U., Ferreira, D. & Westman, E. The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Sci. Rep. 8, 8431 (2018).
Delmotte, K., Schaeverbeke, J., Poesen, K. & Vandenberghe, R. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease. Alzheimers Res. Ther. 13, 84 (2021).
Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat. Commun. 11, 1683 (2020).
Barthelemy, N. R. et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification. Alzheimers Res. Ther. 12, 26 (2020).
Soldan, A. et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 92, E1567–E1579 (2019).
Gordon, B. A. et al. Longitudinal β-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 73, 1192–1200 (2016).
Vos, S. J. et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 138, 1327–1338 (2015).
Chung, J. K. et al. The effects of cortical hypometabolism and hippocampal atrophy on clinical trajectories in mild cognitive impairment with suspected non-Alzheimer’s pathology: a brief report. J. Alzheimers Dis. 60, 341–347 (2017).
Wisse, L. E. M. et al. Suspected non-AD pathology in mild cognitive impairment. Neurobiol. Aging 36, 3152–3162 (2015).
Altomare, D. et al. Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology 93, e1635–e1646 (2019).
Vos, S. J. B. et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol. Aging 44, 1–8 (2016).
Baldeiras, I. et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment. Alzheimers Res. Ther. 10, 33 (2018).
Soldan, A. et al. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol. 73, 698–705 (2016).
Toledo, J. B. et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol. Commun. 2, 26 (2014).
Burnham, S. C. et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol. 15, 1044–1053 (2016).
Bos, I. et al. Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer’s disease. Alzheimers Dement. 15, 1149–1159 (2019).
Calvin, C. M. et al. Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study. Alzheimers Res. Ther. 12, 143 (2020).
Knopman, D. S. et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann. Neurol. 73, 472–480 (2013).
Delvenne, A. et al. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer’s disease pathophysiology. Alzheimers Dement. 19, 807–820 (2023).
Alcolea, D. et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology 85, 626–633 (2015).
Hohman, T. J. et al. APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer’s disease. PLoS ONE 12, e0188501 (2017).
Schreiber, S. et al. Alzheimer disease signature neurodegeneration and APOE genotype in mild cognitive impairment with suspected non-Alzheimer disease pathophysiology. JAMA Neurol. 74, 650–659 (2017).
Thal, D. R. et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition. Acta Neuropathol. 136, 557–567 (2018).
La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 15, 205–216 (2019).
Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).
Willemse, E. A. J. et al. Comparing CSF amyloid-β biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement. 13, e12182 (2021).
Lowe, V. J. et al. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimers Dement. 15, 927–939 (2019).
Vos, S. J. et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol. 12, 957–965 (2013).
Wisse, L. E. M. et al. Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology. Alzheimers Res. Ther. 13, 100 (2021).
Thal, D. R., Rub, U., Orantes, M. & Braak, H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791–1800 (2002).
Crary, J. F. et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766 (2014).
Duyckaerts, C. et al. PART is part of Alzheimer disease. Acta Neuropathol. 129, 749–756 (2015).
Thal, D. R. & Tome, S. O. The central role of tau in Alzheimer’s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res. Bull. 190, 204–217 (2022).
Walkiewicz, G. et al. Primary retinal tauopathy: a tauopathy with a distinct molecular pattern. Alzheimers Dement. 20, 330–340 (2024).
Shi, Y. et al. Cryo-EM structures of tau filaments from Alzheimer’s disease with PET ligand APN-1607. Acta Neuropathol. 141, 697–708 (2021).
Kaufman, S. K., Del Tredici, K., Thomas, T. L., Braak, H. & Diamond, M. I. Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer’s disease and PART. Acta Neuropathol. 136, 57–67 (2018).
Aragao Gomes, L. et al. Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. Acta Neuropathol. 141, 173–192 (2021).
Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969 (2011).
Santa-Maria, I. et al. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 124, 693–704 (2012).
Farrell, K. et al. Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathol. 143, 33–53 (2022).
Teylan, M. et al. Clinical diagnoses among individuals with primary age-related tauopathy versus Alzheimer’s neuropathology. Lab. Invest. 99, 1049–1055 (2019).
Glenner, G. G. & Wong, C. W. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885–890 (1984).
Thal, D. R., Ghebremedhin, E., Orantes, M. & Wiestler, O. D. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62, 1287–1301 (2003).
Thal, D. R. et al. Pathology of clinical and preclinical Alzheimer’s disease. Eur. Arch. Psychiatry Clin. Neurosci. 263, S137–S145 (2013).
Charidimou, A. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 21, 714–725 (2022).
Boyle, P. A. et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology 85, 1930–1936 (2015).
Hyman, B. T. et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 8, 1–13 (2012).
Ellis, R. J. et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, Part XV. Neurology 46, 1592–1596 (1996).
Selnes, O. A. & Vinters, H. V. Vascular cognitive impairment. Nat. Clin. Pract. Neurol. 2, 538–547 (2006).
Thal, D. R. et al. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging 30, 1936–1948 (2009).
Hecht, M., Kramer, L. M., von Arnim, C. A. F., Otto, M. & Thal, D. R. Capillary cerebral amyloid angiopathy in Alzheimer’s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 135, 681–694 (2018).
Gorelick, P. B. et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 2672–2713 (2011).
Skrobot, O. A. et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain 139, 2957–2969 (2016).
Vinters, H. V. et al. Neuropathologic substrates of ischemic vascular dementia. J. Neuropathol. Exp. Neurol. 59, 931–945 (2000).
Launer, L. J., Hughes, T. M. & White, L. R. Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann. Neurol. 70, 774–780 (2011).
Thal, D. R. et al. Stages of granulovacuolar degeneration: their relation to Alzheimer’s disease and chronic stress response. Acta Neuropathol. 122, 577–589 (2011).
Simchowicz, T. in Histologie und histopathologische Arbeiten über die Großhirnrinde mit besonderer Berücksichtigung der pathologischen Anatomie der Geistekrankheiten Vol. 4 (eds Nissl, F. & Alzheimer, A.) 267–444 (Fischer, 1911).
Ball, M. J. & Lo, P. Granulovacuolar degeneration in the ageing brain and in dementia. J. Neuropathol. Exp. Neurol. 36, 474–487 (1977).
Funk, K. E., Mrak, R. E. & Kuret, J. Granulovacuolar degeneration (GVD) bodies of Alzheimer’s disease (AD) resemble late-stage autophagic organelles. Neuropathol. Appl. Neurobiol. 37, 295–306 (2011).
Kohler, C. Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. Acta Neuropathol. 132, 339–359 (2016).
Koper, M. J. et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease. Acta Neuropathol. 139, 463–484 (2020).
Wiersma, V. I. et al. Granulovacuolar degeneration bodies are neuron-selective lysosomal structures induced by intracellular tau pathology. Acta Neuropathol. 138, 943–970 (2019).
Balusu, S. et al. MEG3 activates necroptosis in human neuron xenografts modeling Alzheimer’s disease. Science 381, 1176–1182 (2023).
Tang, D., Kang, R., Berghe, T. V., Vandenabeele, P. & Kroemer, G. The molecular machinery of regulated cell death. Cell Res. 29, 347–364 (2019).
Koper, M. J. et al. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease. Acta Neuropathol. Commun. 10, 128 (2022).
Josephs, K. A. et al. Updated TDP-43 in Alzheimer’s disease staging scheme. Acta Neuropathol. 131, 571–585 (2016).
Joachim, C. L., Morris, J. H. & Selkoe, D. J. Clinically diagnosed Alzheimer’s disease: autopsy results in 150 cases. Ann. Neurol. 24, 50–56 (1988).
Nelson, P. T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142, 1503–1527 (2019).
Nelson, P. T. et al. LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 145, 159–173 (2023).
Amador-Ortiz, C. et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann. Neurol. 61, 435–445 (2007).
Tome, S. O. et al. TDP-43 pathology is associated with increased tau burdens and seeding. Mol. Neurodegener. 18, 71 (2023).
Braun, D. J. et al. Early chronic suppression of microglial p38ɑ in a model of Alzheimer’s disease does not significantly alter amyloid-associated neuropathology. PLoS ONE 18, e0286495 (2023).
McAleese, K. E. et al. TDP-43 pathology in Alzheimer’s disease, dementia with Lewy bodies and ageing. Brain Pathol. 27, 472–479 (2017).
Mackenzie, I. R. et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1–4 (2010).
Braak, H. & Braak, E. Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria. J. Neural Transm. 105, 801–819 (1998).
Thal, D. R. et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer’s disease-related pathology. Neuropathol. Appl. Neurobiol. 31, 270–279 (2005).
Thal, D. R. et al. Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. J. Neural Transm. 122, 1007–1018 (2015).
Josephs, K. A. et al. Argyrophilic grains: a distinct disease or an additive pathology? Neurobiol. Aging 29, 566–573 (2008).
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211 (2003).
Del Tredici, K., Rub, U., De Vos, R. A., Bohl, J. R. & Braak, H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413–426 (2002).
Brettschneider, J. et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20–38 (2013).
Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).
Van Schoor, E. et al. Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathol. Appl. Neurobiol. 47, 328–345 (2020).
Fernandes Gomes, B. et al. ɑ-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Parkinsonism Relat. Disord. 117, 105807 (2023).
Shen, X. N. et al. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer’s disease pathology and clinical progression in older adults without dementia. Alzheimers Dement. 12, e12104 (2020).
Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement. 9, e12385 (2023).
Nelson, P. T. et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 144, 27–44 (2022).
Hamilton, R. L. Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using ɑ-synuclein immunohistochemistry. Brain Pathol. 10, 378–384 (2000).
Lippa, C. F. et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153, 1365–1370 (1998).
Uchikado, H., Lin, W. L., DeLucia, M. W. & Dickson, D. W. Alzheimer disease with amygdala Lewy bodies: a distinct form of α-synucleinopathy. J. Neuropathol. Exp. Neurol. 65, 685–697 (2006).
Vonsattel, J. P. et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann. Neurol. 30, 637–649 (1991).
Mandybur, T. I. Cerebral amyloid angiopathy: the vascular pathology and complications. J. Neuropathol. Exp. Neurol. 45, 79–90 (1986).
Dickson, D. W., Kouri, N., Murray, M. E. & Josephs, K. A. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45, 384–389 (2011).
Jansen, W. J. et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. JAMA Neurol. 79, 228–243 (2022).
Mormino, E. C. et al. Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol. 73, 1185–1191 (2016).
Murray, M. E. et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum. Brain 138, 1370–1381 (2015).
Tan, M.-S. et al. Longitudinal trajectories of Alzheimer’s ATN biomarkers in elderly persons without dementia. Alzheimers Res. Ther. 12, 55 (2020).
Acknowledgements
The authors thank P. Scheltens for the conception of this manuscript.
Author information
Authors and Affiliations
Contributions
S.J.B.V. and A.D. researched data for the article. S.J.B.V., A.D. and P.J.V. contributed substantially to discussion of the content. All authors wrote the article and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
S.J.B.V. has received funding from ZonMW (SNAP VIMP grant no. 7330505021), Stichting Adriana van Rinsum-Ponssen and the EPND project, which received funding from the European Commision, IMI 2 Joint Undertaking (JU) under grant agreement no. 101034344. The IMI JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. D.R.T. has received speakers’ honoraria from Biogen and travel reimbursement from UCB and has collaborated with Novartis Pharma AG, Probiodrug, GE-Healthcare and Janssen Pharmaceutical Companies. He receives funding from Stichting Alzheimer Onderzoek (SAO/FRA 2020/017), Fonds Wetenschappelijk Onderzoek (Vlaanderen) (G0F8516N, G065721N), Alzheimer Association (22-AAIIA-963171) and KU-Leuven Internal Funding (C14/22/132; C3/20/057). P.J.V. has received funding from the European Commission, IMI 2 JU, AMYPAD grant no. 115952; European Commission, IMI 2 JU, RADAR-AD grant no. 806999; and European Commission, IMI 2 JU, EPND grant no. 101034344. He has also received funding from Zon-MW, Redefining Alzheimer’s disease, grant no. 733050824736; and Biogen (Amyloid Biomarker Study Group). Grants were paid to the university. A.D. and C.R.J. declare no competing interests.
Peer review
Peer review information
Nature Reviews Neurology thanks J. Hort and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Glossary
- AD polygenic risk score
-
A score that represents an individual’s predicted genetic susceptibility to AD. The score aggregates the genetic effects of single nucleotide variants identified in genome-wide association studies in AD.
- Centiloid value
-
A unit that allows amyloid PET signals obtained with different radiotracers to be combined. Centiloid values can range from 0 (amyloid-β-negative brain) to 100 (typical Alzheimer disease (AD)).
- Standardized uptake value ratio
-
The mean activity concentration in predefined anatomically relevant cortical regions of interest compared with that in a reference region.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Vos, S.J.B., Delvenne, A., Jack, C.R. et al. The clinical importance of suspected non-Alzheimer disease pathophysiology. Nat Rev Neurol 20, 337–346 (2024). https://doi.org/10.1038/s41582-024-00962-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-024-00962-y
- Springer Nature Limited